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Aim: Infants hospitalized for bronchiolitis undergo examinations and treatments not supported by 
current research evidence guidelines. We investigated practice variations among Finnish children 
hospitalised for bronchiolitis. 
Methods: Prospective, multi-centre cohort study was conducted in paediatric units in three 
University Hospitals in Finland during 2008-2010. Children under the age of two years 
hospitalised for bronchiolitis were enrolled. Hospital medical records were reviewed to collect 
data on clinical course, testing and treatments. Data were analysed separately for children 
meeting our strict definition of bronchiolitis, age <12 months without history of wheeze, and a 
loose definition, age 12-23 months or with history of wheezing episode. 
Results:  Among 408 enrolled children, the median age was 8.1 months. Stratifying by strict and 
loose bronchiolitis subgroups, clinical management varied between the three hospitals: complete 
blood count (ranges for strict 15-95%; loose 16-94%), chest x-ray (strict 16-91%; loose 14-72%), 
intravenous fluids (strict 2-47%; loose 2-41%), use of nebulised epinephrine (strict 10-84%; loose 
7-50%), use of salbutamol (strict 18-21%; loose 13-84%), and use of corticosteroids (strict 6%-
23%; loose 60-76%).  
Conclusions: Clinical management of bronchiolitis varied considerably by institution whether 
using either definitions of bronchiolitis. A stronger commitment to evidence-based bronchiolitis 
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Key Notes 
x Many infants hospitalized for bronchiolitis undergo examinations and treatments not 
supported by current research evidence.  
x We found that clinical management of bronchiolitis varies considerably by institution 
whether using the strict or loose definitions of bronchiolitis.  
x A stronger commitment to evidence-based bronchiolitis guidelines is needed. As a result 
of our findings we recommend that further guidelines should separate these two 




 Bronchiolitis is a lower respiratory tract viral infection in young children. Most European 
countries limit the diagnosis of bronchiolitis to infants age 12 months or younger and typically do 
not allow previous history of wheezing, whereas the USA uses an older age limit of less than 24 
months (1). Bronchiolitis is one of the most common and costly respiratory illnesses in infants 
and young children (2). Approximately 100,000 bronchiolitis admissions occur annually in the 
USA at an estimated cost of $1.7 billion (3). In Finland, up to 3% of infants with bronchiolitis 
under 12 months of age are hospitalized, and up to 9% require intensive care (4). In Finland, the 
mean hospitalization cost for a bronchiolitis patient is €1,800 and goes up to €8,000 if paediatric 
intensive care is needed (4).  
 Several randomized controlled trials and systematic reviews have attempted to identify 
the optimal treatments for children with bronchiolitis (5-8). Evidence-based care remains largely 
supportive, including adequate oxygenation, mucus extraction, and nutrition. Despite 
international guidelines on bronchiolitis, the overuse of diagnostic testing, i.e. chest radiography 
and laboratory testing, and ineffective therapy, i.e.beta agonists, antibiotics, corticosteroids, 
remain common. The main reason for the overuse of testing and medications is the modest 
effectiveness of bronchiolitis guidelines in modifying physician behaviour (9-11).  
 In response to these problems, many hospitals have implemented clinical practice 
guidelines and recommendations based on evidence-based guidelines for bronchiolitis (12). These 
guidelines seldom recommend specific interventions but rather try to prevent the use of irrelevant 
diagnostic tests or ineffective drug treatments or other interventions.  Despite the high frequency 
and cost of bronchiolitis care, there has been limited research on variability of care among 
different hospitals (9,13,14). Therefore, our aim was to investigate bronchiolitis-related practice 
variation in three tertiary care hospitals in Finland. Due to the expected variability in the 
diagnostic and management practices, we wanted to investigate practice variation in two 
subgroups of children less than two years of age who were hospitalized for bronchiolitis: 1) those 
who met our strict definition of bronchiolitis, i.e., age under 12 months of age without history of 






This prospective, multicentre cohort study was conducted as part of the Multicenter 
Airway Research Collaboration, a programme of the Emergency Medicine Network, during two 
consecutive winter seasons (November through March) in years 2008 to 2010. The study was 
carried on in the paediatric departments of three Finnish tertiary care university hospitals in 
Turku, Tampere and Kuopio, Finland (15). As in its USA counterpart study (16), a standardized 
protocol was used to enrol a target number of consecutive patients from the inpatient ward and 
the intensive care unit. Inclusion criteria were an attending physician’s diagnosis of bronchiolitis, 
age under two years, and informed consent from a guardian. Patients were enrolled within 18 
hours of admission. The exclusion criteria were previous enrolment or transfer to a participating 
hospital over 48 hours after the original admission time. All patients were treated at the discretion 
of the treating physician. The institutional review board of Turku University Hospital approved 
the study, and this approval covered all participating hospitals in Finland.  
 
Data collection 
Investigators conducted a standardized structured interview on patients’ demographic, 
environmental and clinical characteristics (17). Patients were evaluated daily in the ward by a 
physician. Hospital medical records were used to collect clinical data from the pre-admission 
evaluation in the emergency department as well as the child’s inpatient course. These data were 
manually reviewed at the Emergency Medicine Network Coordinating Center and site 
investigators were queried about missing or discrepant data. 
To evaluate bronchiolitis severity, a modified Respiratory Distress Severity Score 
(RDSS) was calculated based on four assessments made during the pre-admission visit: 
respiratory rate by age, presence of wheezing (yes or no), air entry (normal, mild difficulty, or 
moderate to severe difficulty), and retractions (none, mild, or moderate to severe) (15,18). Each 
component was assigned a score of zero, one, or two, with the exception of wheezing, which was 
assigned either zero (no wheezing) or two (wheezing), and then summed for a possible total score 
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of zero to eight per patient. When a child had one or two of the RDSS components missing 
(n=174), single imputation controlling for age, respiratory rate, presence of wheezing, air entry, 
and retractions, was used to generate the score. RDSS values were not calculated for the 15 
patients missing data for more than two components of the score.  
 
Nasopharyngeal aspirate collection and viral testing 
Nasopharyngeal aspirates were collected at study entry using a standardized protocol 
(19). The sample was added to transport medium, immediately placed on ice, and then stored at -
80oC before analysis at Baylor College of Medicine. All polymerase chain reaction (PCR) assays 
were conducted as singleplex or duplex two-step real time PCR and used for the detection of 
RNA respiratory viruses; respiratory syncytial virus (RSV) types A and B, rhinovirus (RV) 
covering A, B and C species, parainfluenza virus types 1, 2 and 3, influenza virus types A, B and 
2009 novel H1N1, human metapneumovirus, coronaviruses NL-63, HKU1, OC43 and 229E, 
enteroviruses and DNA pathogens for adenovirus. Details of the methods and primers and probes 
have been described previously (20,21).  
  
Statistical analyses 
All analyses were performed using Stata 14.1 (StataCorp LLC, Texas, USA). Data are 
presented as proportions and means with 95% confidence intervals (95%CIs) or medians with 
interquartile ranges (IQRs). For analytical purposes, we divided the cohort into two subgroups by 
bronchiolitis definition:  children under 12.0 months of age with no history of wheeze (strict 
bronchiolitis) or all other children in the cohort who were 12.0-23.9 months of age or had a 
history of wheeze (loose bronchiolitis).  
To assess variability in care by study site, bivariate associations were tested using chi-
square, and Fisher’s exact test, and Kruskall-Wallis test, as appropriate. To evaluate the effect of 
patient characteristics on practice variation between study sites, we created two multilevel mixed-
effects logistic regression models for each test and treatment of interest and then calculated each 
model’s corresponding intraclass correlation coefficient (ICC).  The first model accounted for 
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random site effects, but did not adjust for patient-level characteristics.  The second, more 
complete model specified random site effects while simultaneously adjusting for patient-level 
characteristics; i.e., age, sex, insurance provider, major relevant comorbid disorder, and RDSS. 
Therefore, the ICCs derived from our models that specify only random site effects represent the 
proportion of the total outcome variation that is attributable to site level differences without 
adjusting for patient-level characteristics. The ICCs from our complete models represent the total 
outcome variation that is attributable to site level differences after accounting for differences in 
patient-level characteristics.  




Study cohort and patient characteristics 
Altogether, 408 hospitalized children with bronchiolitis were enrolled (Table 1). Site A 
enrolled 135 patients, Site B 135 and Site C 138 patients. The median travel distances between 
home and hospital were13 km for Site A, 47 km for Site B, and 21 km for Site C (p<0.001). 
Among all children hospitalized for bronchiolitis, the median age was 8.1 months (IQR 3.3-14.8), 
they were more often male (62%), 24% had parents with asthma, and 37% had history of previous 
wheezing.  Additionally, 13% were premature and 12% had major relevant comorbid disorder. 
Virology testing revealed that 43% were RSV positive and 32% were RV positive, both with and 
without other detected viruses. 
Of all children, 206 (50%) children met our strict definition of bronchiolitis while 202 
met the loose definition. Children with strict bronchiolitis were younger partly due to definition, 
had generally lower RDSS score although exclusively included intensive care unit patients, had 
RSV more often, and rhinovirus less often (all p<0.001) (Table 1).  
 
Patient characteristics by site 
Overall, patient characteristics did not differ by site for sex, race, prematurity or parental 
history of asthma. However, median age of patients and comorbidity varied between sites: at Site 
A the median age of patients was 6.0 months, at Site B it was 8.1 months and at Site C it was 10.4 
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months (p<0.001). Comorbidity was highest 17% at Site A, it was 13% at Site B and only 6% at 
Site C (p=0.01). Also, RDSS varied significantly by site: the mean RDSS was highest 5.3 at Site 
A, it was 5.1 at Site C and 4.0 at Site B (p<0.001). Taken together, Site A treated younger, more 
severely ill patients with highest proportion of comorbid disorders. 
 
Testing and medical interventions by site, stratified by bronchiolitis definition 
Diagnostic testing differed significantly between the hospital sites (Fig. 1). Among 
children with strict bronchiolitis (Fig. 1A), complete blood count (CBC) and chest x-ray were 
performed for nearly all patients at Site B (95% and 91%, respectively), and only few patients at 
Site A (15% and 18%, respectively) (both p<0.001). At Site C, CBC was performed from 61% 
and chest x-ray from 16% of patients with strict bronchiolitis. Intravenous fluids were given to 
47% of the patients at Site B, and 8% and 2% of patients at Site A and C (p<0.001). 
Among children with loose bronchiolitis (Fig. 1B), the amount of diagnostic testing 
remained high at Site B (CBC 94%, chest x-ray 72%), and remained low at Site A (16%, and 
14%, respectively), and C (60% and 20%, respectively) (both p<0.001). Also, the difference in 
giving intravenous fluids between hospitals varied. Intravenous fluids were given to 41% of 
patients at Site B, and 2% and 7% of patients at Site A and C (p<0.001). 
 
Medical treatments by site, stratified by bronchiolitis definition 
There were also marked differences in medical treatments between the sites (Fig. 2). 
Among children with strict bronchiolitis (Fig. 2A), the use of nebulised epinephrine was lowest at 
Site A (10%), highest at Site B (84%), and intermediate at Site C (49%) (p<0.001). No difference 
between sites was found in the use of salbutamol (p=0.95), nor in the use of antibiotics (p=0.21). 
Use of corticosteroids was 6% at Site A, 8% at Site B, and 23% at Site C (p=0.03). 
Among children with loose bronchiolitis (Fig. 2B), the use of bronchodilators differed 
between the study sites. The use of nebulised epinephrine was 8% at Site A, 50% at Site B, and 
7% at Site C (p<0.001). The use of salbutamol was 84% at Site A, 78% at Site B, and 13% at Site 
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C (P<0.001). No difference between sites was found in the use of antibiotics (p=0.13), nor in the 
use of corticosteroids (p=0.26).  
  
 
Inter-site variability with adjustment for patient characteristics 
To evaluate the effect of patient characteristics on care variability between study sites, we 
calculated ICCs from mixed-effects logistic regression models (Table 2).  Overall, comparing the 
ICCs from models that excluded patient characteristics (Model A) and the ICCs from models that 
adjusted for patient demographic and clinical characteristics (Model B), the site-attributable 
variability remained relatively consistent for each outcome after adjustment.  
In the strict bronchiolitis subgroup, salbutamol and inpatient antibiotic use exhibited the 
lowest percentages of site-attributable variability (all ICCs <1%), while performance of CBC, 
chest x-ray, intravenous fluids, and use of epinephrine demonstrated the highest percentages of 
variability (all ICCs >40%). 
In the loose bronchiolitis subgroup, use of corticosteroids and antibiotics demonstrated 
the lowest percentages of site-attributable variability (all ICCs <5%), while CBC performed and 




We found that use of diagnostic tests and treatment varied considerably between three 
Finnish hospitals whether a strict or loose definitions of bronchiolitis was used. Variability was 
not explained by the differences in patient demographics or clinical characteristics. Excessive 
diagnostic testing and treatments of bronchiolitis may have adverse effects and will certainly 
increase costs. Therefore, the latest 2014 American Academy of Pediatrics, 2015 National 
Institute for Health and Care Excellence and 2016 Finnish bronchiolitis guidelines recommend the 
supportive care of bronchiolitis with adequate oxygenation and nutrition (12,22,29). Our study 
was performed during 2008-2010, before publication of these latest guidelines, which may explain 
some of the excessive testing and treatments observed.  
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 Considering diagnostics of bronchiolitis, we found that use of CBC and chest 
radiography was more common in both clinical subgroups at Site B, although the patients 
presented with a comparatively less severe illness. According to guidelines, clinicians should 
diagnose bronchiolitis and assess disease severity on the basis of history and physical 
examination and radiographic or laboratory studies should not be obtained routinely (12,22,29). 
However, clinicians should assess risk factors for severe disease, such as age less than 12 weeks, 
a history of prematurity, underlying cardiopulmonary disease, or immunodeficiency, when 
making decisions about evaluation and management of children with bronchiolitis. We speculate 
that the long travel distances between home and hospital at Site B might explain some of these 
results. If the distance between home and hospital is long, the pressure to perform diagnostic tests 
and give treatments before discharge might be higher. 
In the treatment of bronchiolitis, the largest site differences were found in the use of 
epinephrine among children with strict definition of bronchiolitis, and in the use of epinephrine 
and salbutamol among those with loose definition of bronchiolitis. On the contrary, the variability 
of corticosteroid use was rather low, but it was used quite often among children with loose 
definition of bronchiolitis. Use of nebulized epinephrine in bronchiolitis patients less than 12 
months was national practice in Finland before new randomized trials were published (23-25). 
This practice was also seen in the study comparing Finnish and Swedish bronchiolitis treatment 
practices (14). According to recent guidelines, beta agonists and corticosteroids are the most 
commonly overused, non-evidence-based therapies (12,22,29). Several studies and reviews have 
evaluated the use of bronchodilators for bronchiolitis patients under two years old, but most 
randomized controlled trials have failed to demonstrate a consistent benefit (6). The same is true 
for use of corticosteroids (8,26). The major limitation of these earlier studies was that a subgroup 
of high asthma risk children was not evaluated separately (20,21). However, much of the 
continued use of bronchodilators and corticosteroids may arise from similarities in the signs and 
symptoms between bronchiolitis and asthma, especially with those children close to age 2 years 
having risk factors for asthma or recurrent wheezing (27,28). It is not surprising that clinician 
choose to try beta agonists for these older children with asthma risk factors. Most likely, a 23-
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month-old child with RV infection and a history of wheeze has a different kind of disease than a 
three-month-old infant with RSV. Since the current guidelines do not separate these two 
subgroups, it might be that what is true for the treatment of strict definition of bronchiolitis is not 
necessarily true for treatment of loose definition of bronchiolitis. 
 Of other treatments, use of intravenous fluids varied greatly in both bronchiolitis 
subgroups, with Site B preferring intravenous fluids more than the other sites. We speculate that 
the other sites more often used nasogastric tube for hydration, but these data were not collected in 
our study. Guidelines do not prefer either hydration methods, but nasogastric tube can be 
considered more physiological, and easier to implement, although it may trap mucus and prolong 
wheezing. Variability in the use for antibiotics was low. 
The strengths of our study included a multiyear, multicentre cohort of severely ill 
bronchiolitis patients, with adjustment for demographic and clinical factors. We evaluated several 
clinical factors that might have influenced clinical decision-making including parent history of 
asthma, history of previous wheeze, RDSS, fever and comorbid conditions, but these factors did 
not explain the variability of practice. Our cohort represented severe bronchiolitis cases because 
all were admitted to hospital. Therefore, ideally there should have been less observed site 
variability in tests and treatments. In this paper, we show that even after adjusting for 
demographic and clinical factors, wide variations between hospitals persisted. Furthermore, wide 
variation in practice was seen between strict and loose bronchiolitis subgroups. However, this 
study was not designed to determine the causes for the practice variation; reasons for testing and 
treatment were not queried. Also, the study was performed before publication of the current 
guidelines, so we do not know how well the latest guidelines are followed. The follow-up studies 
are currently on going. 
 
CONCLUSION 
We observed marked differences in diagnostic testing and treatments for bronchiolitis 
both in children with strict or loose definitions of bronchiolitis. Many infants hospitalised for 
bronchiolitis undergo examinations and treatments not supported by current research evidence or 
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guidelines for bronchiolitis. These results call for stronger commitment to the evidence-based 
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 FIGURE LEGENDS 
 
Figure 1. Diagnostic tests and medical interventions by hospital study site for patient subgroups 
with A) strict definition of bronchiolitis (age <12 months without history of wheeze) and B) loose 
definition of bronchiolitis (age 12-23 months or with history of wheeze). All p<0.001. 
Abbreviations: CBC, complete blood count; IV, intravenous fluids. 
 
Figure 2. Medication administered during hospitalization by hospital study site for patient 
subgroups with A) strict definition of bronchiolitis (age <12 months without history of wheeze) 
and B) loose definition of bronchiolitis (age 12-23 months or with history of wheeze).  
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Abbreviations: IQR, interquartile range; RDSS, respiratory distress severity score; ICU, intensive care unit; LOS, length of stay; RSV respiratory 




Table 2. Intraclass Correlation Coefficient assessing inter-site variability in the use of  





Strict bronchiolitis, n=206 
Model A: site random effects  
Model B: site random effects with 
adjustment for patient 
characteristics* 
Outcomes ICC (%) 95%CI ICC (%) 95%CI 
CBC performed 53% 17% 86% 56% 18% 88% 
Chest x-ray performed 50% 16% 85% 52% 17% 86% 
IV received  41% 9.8% 82% 56% 18% 89% 
Nebulized epinephrine given 43% 12% 80% 42% 12% 81% 
Nebulized salbutamol given 0% 0% 0% 0% 0% 0% 
Corticosteroids 8.4% 0.6% 58% 17% 1.8% 70% 
Antibiotics 0.1% 0% 100% 0.4% 0% 100% 
Loose bronchiolitis, n=202 
Model A: site random effects  
Model B: site random effects with 
adjustment for patient 
characteristics* 
Outcomes ICC (%) 95%CI ICC (%) 95%CI 
CBC performed 50% 15% 85% 53% 16% 87% 
Chest x-ray performed 31% 7.4% 71% 33% 7.7% 74% 
IV received  36% 7.7% 79% 33% 6.3% 79% 
Nebulized epinephrine given 31% 6.7% 73% 37% 7.9% 80% 
Nebulized salbutamol given 44% 13% 81% 48% 14% 84% 
Corticosteroids 0% 0% 0% 4.1%      0.1% 67% 
Antibiotics 1.0% 0% 73% 3.7% 0.2% 43% 
 
*Age, sex, insurance, major relevant comorbid disorder, respiratory distress severity score (RDSS) 








Diagnostic tests and medical interventions by hospital study site for patient subgroups with (A) strict 
definition of bronchiolitis (age <12 months without history of wheezing) and (B) loose definition of 
bronchiolitis (age 12–23 months or with history of wheezing). All p < 0.001. Abbreviations: CBC, 
complete blood count; IV, intravenous fluids. 
Figure 2 
Medication administered during hospitalization by hospital study site for patient subgroups with (A) strict 
definition of bronchiolitis (age <12 months without history of wheezing) and (B) loose definition of 
bronchiolitis (age 12–23 months or with history of wheezing). 
